Related Experiment Video
Updated: Jun 19, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target
Hayley C Whitaker1, Anne Y Warren, Rosalind Eeles
1Uro-Oncology Research Group, CRUK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK. hayley.whitaker@cancer.org.uk
Background:
Recent genome-wide association studies have shown an association of a SNP two base pairs upstream of the 5' UTR of the microseminoprotein-beta (MSMB) gene with an increased risk of developing the prostate cancer, re-igniting interest in its protein product, MSMB.
Methods:
As one of the most abundant prostatic proteins, MSMB can be reliably detected in tissue and serum.
Results:
It has been consistently shown that MSMB expression is high in normal and benign prostate tissue and lowered or lost in prostate cancer suggesting that it might be a useful tissue biomarker for prostate cancer diagnosis and its levels in serum may be useful as a marker for prognosis. Members of the cysteine-rich secretory protein family and laminin receptors have been shown to bind MSMB at the cell surface and in serum thereby regulating apoptosis. Thus, in the benign prostate, MSMB regulates cell growth, but when MSMB is lost during tumourigenesis, cells are able to grow in a more uncontrolled manner. Both full length MSMB and a short peptide comprised of amino acids 31-45 have been tested for potential therapeutic benefit in mouse models and humans.
Conclusions:
MSMB has potential as a biomarker of prostate cancer development, progression and recurrence and potentially as a target for therapeutic intervention.
Insights
Microseminoprotein-beta (MSMB) is a promising prostate cancer biomarker. Its reduced levels in tumors suggest potential for diagnosis and prognosis, with therapeutic applications also under investigation.
Area of Science:
- Molecular biology
- Oncology
- Biochemistry
Background:
- Recent genome-wide association studies link a single nucleotide polymorphism (SNP) near the microseminoprotein-beta (MSMB) gene to increased prostate cancer risk.
- This finding has renewed interest in the MSMB protein and its role in prostate cancer.
Purpose of the Study:
- To investigate the potential of MSMB as a biomarker for prostate cancer diagnosis, prognosis, and therapeutic intervention.
- To understand the role of MSMB in prostate cell growth regulation and apoptosis.
Main Methods:
- Detection of MSMB protein in prostate tissue and serum.
- Analysis of MSMB expression levels in normal, benign, and cancerous prostate tissues.
- Investigating the interaction of MSMB with cell surface proteins and its effect on apoptosis.
- Evaluating the therapeutic potential of full-length MSMB and a specific peptide in preclinical and clinical models.
Main Results:
- MSMB is highly expressed in normal and benign prostate tissues but downregulated or lost in prostate cancer.
- MSMB levels in serum may serve as a prognostic marker.
- MSMB regulates cell growth in the benign prostate; its loss contributes to uncontrolled tumor cell proliferation.
- Interactions with cell surface proteins and laminin receptors modulate MSMB's effect on apoptosis.
Conclusions:
- MSMB demonstrates significant potential as a biomarker for prostate cancer development, progression, and recurrence.
- MSMB may also serve as a viable target for therapeutic strategies in prostate cancer treatment.
